Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

23/09 Earnings release - Q2 2026

More about the company

Market Cap	1.17Cr 1.34Cr 1.09Cr 99.84L 1.89Cr 128.29Cr 1.91Cr 13Cr 5.03Cr 64Cr 5.05Cr 4.94Cr 214.17Cr	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	99.75L 1.15Cr 92.84L 85.24L 1.61Cr 109.54Cr 1.63Cr 11Cr 4.3Cr 55Cr 4.31Cr 4.21Cr 182.86Cr	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	34.3%	Yield 2024 *	-	Yield 2025	-

14/07	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC	CI
14/07	Celyad Oncology to Raise Funds via Private Placement	MT
15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/25/29	Celyad Oncology announces research facility divestiture	RE
29/25/29	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/25/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/25/29	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/25/28	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/25/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/25/24	Celyad Oncology Announces Strategic Review	CI

28/22/28	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/22/11	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/21/06	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/21/26	CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/20/08	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

29/07	Celyad Oncology : Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)	PU
14/07	Celyad Oncology : Announces €500,000 Private Placement	PU
20/05	Celyad Oncology : AGM Minutes - informal translation EN	PU
02/04	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/25/29	Celyad Oncology : Announces Research Facility Divestiture	PU

29/07	Celyad Oncology : Publication d’une notification de transparence reçue de Tolefi SA (Article 14§1 de la Loi du 2 Mai 2007)
18/07	Rustige start cijferseizoen in Brussel
14/07	Celyad kondigt private plaatsing van 500.000 euro aan
20/05	Celyad Oncology : AGO Procès Verbal - version FR
17/04	Celyad Oncology : Rapport Annuel 2025 FR

Celyad SA Share Price Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation: Celyad SA

Latest news : Celyad SA

Analysts' recommendations: Celyad SA

Press Releases: Celyad SA

News in other languages: Celyad SA

Quotes and Performance

Managers and Directors: Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Serge Goblet BRD	Director/Board Member	-	01/01/2008
Hilde Windels CHM	Chairman	61	23/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	1.34Cr
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+12.94%	4.85TCr
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+472.09%	3.99TCr
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.27%	3.87TCr
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+66.52%	3.51TCr
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+44.64%	2.98TCr
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+126.06%	1.61TCr
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	1.61TCr
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+14.79%	1.36TCr
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.97%	1.26TCr
Average	-3.87%	+1.05%	+62.16%	+88.67%	2.78TCr
Weighted average by Cap.	-1.60%	+2.03%	+79.78%	+107.48%

	2024	2025
Net sales	2L 2L 2L 2L 3L 2.04Cr 3L 20.41L 8L 1.02Cr 8L 8L 3.41Cr	21T 24.16T 19.55T 17.95T 33.89T 23.06L 34.41T 2L 90.43T 11.48L 90.73T 88.73T 38.5L
Net income	-58.24L -67L -54.21L -49.77L -93.99L -64Cr -95.44L -6.39Cr -2.51Cr -32Cr -2.52Cr -2.46Cr -106.76Cr	8L 10L 8L 7L 13.39L 9.11Cr 13.6L 91.06L 35.74L 4.54Cr 35.86L 35.07L 15Cr
Net Debt	-32.95L -37.9L -30.67L -28.16L -53.17L -36Cr -54L -3.62Cr -1.42Cr -18Cr -1.42Cr -1.39Cr -60Cr	-17.08L -19.65L -15.9L -14.6L -27.56L -19Cr -27.99L -1.87Cr -73.55L -9.34Cr -73.79L -72.17L -31Cr